Colostomy News and Research

RSS
Canadian cancer patients cross the border for second opinion

Canadian cancer patients cross the border for second opinion

ConvaTec's Vitala Continence Control Device receives 2010 Medical Design Excellence Award

ConvaTec's Vitala Continence Control Device receives 2010 Medical Design Excellence Award

FDA grants 510(K) clearance to market Vitala Continence Control Device

FDA grants 510(K) clearance to market Vitala Continence Control Device

Loyola surgeon performs complicated laparoscopic procedure

Loyola surgeon performs complicated laparoscopic procedure

Zassi Medical Evolutions forms new company to develop electrical stimulation technology

Zassi Medical Evolutions forms new company to develop electrical stimulation technology

Taoglas launches FLA.01 antenna

Taoglas launches FLA.01 antenna

Chronically ill patients report better quality of life than those with reversible outcomes

Chronically ill patients report better quality of life than those with reversible outcomes

Cisplatin found to be less effective than standard treatment for patients with anal cancer

Cisplatin found to be less effective than standard treatment for patients with anal cancer

Drug infliximab may help ease ulcerative colitis

Drug infliximab may help ease ulcerative colitis

Review examines the management of radiotherapy induced rectourethal fistula

Review examines the management of radiotherapy induced rectourethal fistula

People with severe illnesses and disabilities don't wallow in misery and self-pity

People with severe illnesses and disabilities don't wallow in misery and self-pity

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.